GAITHERSBURG, Md., May 7, 2025 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference.
|
Conference Details: |
||||
|
Fireside Chat |
||||
|
Date: |
Wednesday, May 14, 2025 |
|||
|
Time: |
3:00 – 3:30 p.m. Pacific Time (PT) |
|||
|
Location: |
Las Vegas, NV |
|||
|
Conference |
||||
|
Event: |
Investor Meetings |
|||
|
Date: |
Wednesday, May 14, 2025 |
|||
A webcast of the fireside chat will be available on the Events & Presentations page of the Company’s website at ir.novavax.com. A replay of the webcast will be available for 30 days.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world’s most significant health challenges by leveraging its scientific expertise in vaccines and its cutting-edge technology platform, which includes protein-based nanoparticles and its Matrix-M® adjuvant. The Company’s growth strategy is focused on building new and diversified partnerships via the out-licensing of its technology platform and vaccine assets earlier in the development process. These strategic collaborations are fueled by smart investments in a growing early-stage pipeline starting with the Company’s core expertise in infectious disease and potentially expanding into other disease areas. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Giovanna Chandler
202-709-5563
media@novavax.com
SOURCE Novavax, Inc.
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…